VivoSeq
Musculoskeletal

Bone Fracture

38

Pipeline Programs

2

Active Trials

26

Companies Involved

Bone Fracture is a moderately active landscape with 38 programs across 26 companies. The most active players are TNF Pharmaceuticals, Inc., EMD Serono, Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.. 23 therapies are approved with 5 more in late-stage development.

Pipeline Metrics

Competitive Density

55/100

Pipeline Velocity

0/100

Mech. Concentration

16/100

Completion Rate

70/100

Attrition Rate

19/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Programs by Phase

Modality Breakdown

93%

Small molecule

38 of 41 classified programs — the dominant modality here.

7%ALL OTHERSMonoclonal antibody25%Peptide12%

Small molecule leads; the ring shows all 41 classified programs, each share of the total. Modality classified for 100% of 42 pipeline programs.

Trial Status

16

clinical trials

Completed7 · 44%
Unknown status4 · 25%
Withdrawn2 · 13%
Terminated1 · 6%
Recruiting1 · 6%
Not yet recruiting1 · 6%

Trial Activity

16 trials

Dexketoprofen and Ibuprofen in Long Bone Fractures
Unknown status··Phase 4·NCT06060236·100 enrolled
Oral vs IV Acetaminophen for Long-bone Fracture in Children
Unknown status··Phase 4·NCT05557344·20 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)